Acrivon Therapeutics, Inc.

NasdaqGM:ACRV Stock Report

Market Cap: US$87.7m

Acrivon Therapeutics Future Growth

Future criteria checks 2/6

Acrivon Therapeutics's earnings are forecast to decline at 5.4% per annum while its annual revenue is expected to grow at 69.4% per year. EPS is expected to grow by 11.6% per annum.

Key information

-5.4%

Earnings growth rate

11.60%

EPS growth rate

Biotechs earnings growth25.3%
Revenue growth rate69.4%
Future return on equityn/a
Analyst coverage

Good

Last updated12 Jun 2026

Recent future growth updates

Recent updates

Analysis Article • Mar 27

We're Keeping An Eye On Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Aug 15

Will Acrivon Therapeutics (NASDAQ:ACRV) Spend Its Cash Wisely?

NasdaqGM:ACRV 1 Year Share Price vs Fair Value Explore Acrivon Therapeutics's Fair Values from the Community and select...
Analysis Article • Mar 27

We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Dec 12

Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis

Summary Acrivon Therapeutics is developing a targeted oncology therapy with a companion proteomics-based signature, showing promising activity in their lead compound for certain patients with gynecologic cancers. The pipeline updates indicate progress in clinical trials, enhancing the potential for successful outcomes in targeted cancer treatments. Financially, Acrivon is well-positioned with sufficient funding to advance its pipeline, though risks remain inherent in biotech investments. The bottom-line summary highlights Acrivon's strengths in innovative therapy development, balanced with the risks typical of early-stage biotech ventures. Read the full article on Seeking Alpha
Analysis Article • Nov 17

We're Not Very Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Sep 18

Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects

Summary Acrivon Therapeutics shows promise in precision oncology with its AP3 platform and positive Phase 2 data for ACR-368, indicating potential for significant stock growth. Acrivon’s robust pipeline, including the accelerated development of ACR-2316, and a strong cash position, highlight its commitment to advancing innovative cancer therapies. Despite being pre-revenue and operating at a loss due to high R&D expenses, ACRV maintains a healthy cash balance, crucial for ongoing operations and development. Analysts project a 163.3% upside, with a target price of $21.67 per share, driven by positive clinical data, pipeline advancements, and strong financial health. Read the full article on Seeking Alpha
Analysis Article • Jul 17

Is Acrivon Therapeutics (NASDAQ:ACRV) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Mar 29

Here's Why We're Not Too Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Oct 05

Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jun 22

Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Feb 22

We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Earnings and Revenue Growth Forecasts

NasdaqGM:ACRV - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202817-151-105-1085
12/31/20270-109-91-958
12/31/2026N/A-85-74-818
3/31/2026N/A-77-66-65N/A
12/31/2025N/A-78-65-64N/A
9/30/2025N/A-82-68-66N/A
6/30/2025N/A-86-73-71N/A
3/31/2025N/A-84-70-68N/A
12/31/2024N/A-81-68-66N/A
9/30/2024N/A-77-64-61N/A
6/30/2024N/A-69-55-53N/A
3/31/2024N/A-64-50-48N/A
12/31/2023N/A-60-44-43N/A
9/30/2023N/A-50-40-40N/A
6/30/2023N/A-45-37-36N/A
3/31/2023N/A-37-35-33N/A
12/31/2022N/A-31-32-30N/A
9/30/2022N/A-27-26-24N/A
6/30/2022N/A-20-22-20N/A
3/31/2022N/A-19-19-18N/A
12/31/2021N/A-16-14-14N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACRV is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ACRV is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ACRV is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ACRV's revenue (69.4% per year) is forecast to grow faster than the US market (12.9% per year).

High Growth Revenue: ACRV's revenue (69.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ACRV's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/10 07:33
End of Day Share Price 2026/07/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Acrivon Therapeutics, Inc. is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Li Wang WatsekCantor Fitzgerald & Co.
Silvan TuerkcanCitizens JMP Securities, LLC
Emily BodnarH.C. Wainwright & Co.